Precirix
Description: Precirix develops targeted radiopharmaceuticals using camelid antibodies for cancer treatment, with CAM-H2 in Phase I/II trials for HER2+ cancers.
Country: Belgium
Based in: Brussels
Founded: 2014
Funding Stage: Series A/B
Tags: ['Biotechnology']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
